Press Releases

Sales of $455.3 million vs. $456.5 million in Prior Year QuarterNet income (loss) of $7.1 million vs. $(13.9) million in Prior Year QuarterDiluted EPS of $0.35 vs. $(0.68) in Prior Year QuarterAdjusted EPS of $0.57 vs. $0.71 in Prior Year QuarterAdjusted EBITDA of $49.3 million vs. $55.5 million in Prior Year QuarterCapital expenditures, net of insurance proceeds and sale of assets, of $11.4 million vs. $10.0 million in Prior Year QuarterOperating cash flow of $46.3 million vs. $(22.7) million in Prior Year QuarterFree cash flow of $34.9 million vs. $(37.0) million in Prior Year QuarterPITTSBURGH, May 8, 2026 /PRNewswire/ -- Koppers Holdings Inc. (NYSE:KOP), an integrated global provider of

SEATTLE, May 8, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announces its financial results and provides an update on recent corporate developments for the first quarter ended March 31, 2026. "During the quarter, we made meaningful progress advancing our (Z)-endoxifen development strategy across both oncology and rare disease indications," stated Dr. Steven Quay, M.D., Ph.D., Atossa Therapeutics' President

Continues Enterprise-wide Strategy to Focus on Improving Margins and Cash FlowPITTSBURGH, May 8, 2026 /PRNewswire/ -- Koppers Holdings Inc. (NYSE:KOP), an integrated global provider of treated wood products, wood treatment chemicals and carbon compounds, today announced that it has made a conditional decision to discontinue distillation and chemical manufacturing operations at its facility located in Stickney, Illinois, subject to the satisfaction of any bargaining obligations that might exist with the union that represents certain employees at that facility.  The conditional de

         TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that CEO Thomas Jensen has been invited to participate as a speaker at Precision Medicine Forum Europe 2026, taking place May 11–12, 2026, in Stockholm, Sweden.Presentation Details: Event: Precision Medicine Forum Europe 2026Presentation Title: Dual Inhibition of PARP and WNT: A Novel Drug-Biomarker Combination in Clinical TrialsTrack: OncologyDate: Monday, May 11, 2026Time: 10:20–10:40 CEST Mr. Jensen will discus

Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data Release HOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced a significant advancement in its intellectual property portfolio with the issuance of a Hong Kong patent covering its proprietary method of reconstituting liposomal Annamycin. The newly granted patent (No. 40073244), titled "Method of Reconstituting Liposomal Annamycin," extends protection through June 25, 2040, further reinforcing Moleculin's long-term global exclusivity strategy. The invention is jointly owned with The University of Texas System. This patent r

Fifth Third Bancorp (NASDAQ:FITB) and Fifth Third Financial Corporation ("FTFC") today announced that, in connection with the recently completed merger of Comerica Incorporated with and into FTFC (the "Merger"), with FTFC surviving the Merger as a wholly owned subsidiary of Fifth Third Bancorp, Fifth Third Bancorp has commenced offers to Eligible Holders (as defined herein) to exchange (each an "Exchange Offer" and collectively, the "Exchange Offers") any and all outstanding notes originally issued by Comerica Incorporated and assumed by FTFC as successor by merger as set forth in the table below (the "Existing FTFC Notes") for (1) up to $1,550,000,000 aggregate principal amount of new note

ORLANDO, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- Gencor Industries, Inc. (the "Company" or "Gencor") (NYSE:GENC) announced today net revenue for the quarter ended March 31, 2026 was $33,799,000 compared with $38,204,000 net revenue for the quarter ended March 31, 2025. The decrease in net revenue was primarily due to lower contract equipment revenues recognized over time and associated freight revenue, which resulted from the timing of orders and shipments. As a percentage of net revenue, gross profit margins increased 200 basis points to 31.7% in the quarter ended March 31, 2026, compared to 29.7% in the quarter ended March 31, 2025. Product engineering and development expenses decreased

Strategic integration of Lyocon blue-laser technologies, directed-energy systems and Tekne defense-mobility capabilities positions NUBURU to address next-generation counter-UAV, electronic-warfare and tactical defense opportunities across allied markets NUBURU, Inc. (NYSE:BURU), a dual-use Defense & Security platform company focused on non-kinetic effects, directed-energy technologies, electronic warfare and software-orchestrated defense systems, today provided a major strategic update on the continued expansion of its integrated Defense & Security platform through the advancement of its Lyocon laser roadmap and the ongoing progression of the proposed Tekne transaction and related Golden

SHENZHEN, China, May 8, 2026 /PRNewswire/ -- MicroAlgo Inc. (the "Company" or "MicroAlgo") (NASDAQ:MLGO), today announced the development of an innovative technology—Quantum Architecture Search (QAS), aimed at automatically optimizing the architecture of quantum circuits to enhance the robustness and trainability of VQA, maximizing the potential of quantum computing devices. In the traditional VQA framework, the design of quantum circuit architectures is typically performed manually or based on certain predefined standard architectures. However, the noise and errors in quantum computers are extremely severe in medium-scale devices, making circuit design a critical factor affecting VQA perfor

OCALA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech, Inc. (NYSEAM:AIM) ("AIM ImmunoTech" or the "Company"), a late-stage biotechnology company focused on the discovery and development of drugs for the treatment of cancer, today announced an agreement between the Company and certain accredited investors to exercise certain outstanding Class A, Class B, Class C, Class D, Class E and Class F Warrants (the "Existing Warrants") to purchase up to an aggregate of 8,719,928 shares of common stock at a reduced exercise price of $0.48 per share for gross proceeds of approximately $4.2 million, before deducting placement agent fees and other estimated offering expenses. The Company intends t

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Precious Metals & Critical Minerals Virtual Investor Conference are available for on-demand viewing. Investors, advisors, and analysts can now access presentations at their convenience. REGISTER AND VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests.Schedule 1x1 meetings here. Featured Company Presentations Include: Compan

SAO PAULO, May 8, 2026 /PRNewswire/ -- Itaú Unibanco Holding S.A. ("Company") informs its shareholders and the market in general, pursuant to Article 3, Paragraph 4, item II, of CVM Resolution No. 44/21, that it has replaced the news portal webpage used for the disclosure of its material acts and facts. The Company will henceforth carry out such disclosures through the portal https://mzgroup.com.br/fatos-relevantes/, in a section available for free access. The Company's Registration Form ("Formulário Cadastral") and its Policy for the Disclosure of Material Acts or Facts were re

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate in the following upcoming conferences: 31st Annual Sohn Investment Conference Location: Jazz at Lincoln Center's Frederick P. Rose Hall Date: May 12, 2026 Format: Emerging Company Pavilion, a curated showcase of 8-10 select companies Management: Ozan Pamir, CFO 4th Annual Benchmark Consumer One-On-One Conference Location: New York Athletic Club Date: May 19, 2026 Format: One-on-one meetings Management: Rob Fried, CEO, and Ozan Pamir, CFO If you would like t

TYSONS CORNER, Va. and PETAH TIKVA, Israel, May 8, 2026 /CNW/ -- Cellebrite DI Ltd. (NASDAQ:CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions, today announced that the Company plans to participate in the following investor conferences in May and June: Date: May 18, 2026Conference:J.P. Morgan 2026 Global Technology, Media and Communications ConferencePresentation Time3:30 p.m. ET Format:Fireside ChatCellebrite executive:   Thomas Hogan, chief executive officerDavid Barter, chief financial officerRoni Fialkov, senior vice president, global finan

NORTH CANTON, Ohio, May 8, 2026 /PRNewswire/ -- The board of directors of The Timken Company (NYSE:TKR, www.timken.com)), a global technology leader in engineered bearings and industrial motion, today approved a 2.9 percent increase in the company's quarterly cash dividend, raising it to 36 cents per share. The dividend is payable on May 29, 2026, to shareholders of record as of May 19, 2026. "Timken is pleased to deliver another dividend increase, marking our 13th year of higher annualized dividend payouts," said Lucian Boldea, president and chief executive officer. "This refle

Company Highlights: GAAP net income of $0.6 million, or $0.00 per diluted common shareDistributable earnings1 of $0.07, or $0.18 per diluted common share, excluding $22.9 million of net realized losses from the resolution of certain legacy assetsDeclares cash dividend on common stock of $0.17 per shareServicing portfolio of ~$36.31 billion, agency loan originations of $707.6 millionStructured loan portfolio of ~$12.00 billion, originations of $767.6 million and runoff of $861.0 millionClosed a $762.6 million collateralized securitization vehicle with enhanced leverage, generating ~$35 million of additional liquidityPurchased $30.7 million of stock at an average price of $7.46 per share, or

Global Payments Inc. (NYSE:GPN) today announced that its Integrated and Platforms business has secured the renewal and expansion of its partnership with Lightspeed DMS, a premier provider of integrated dealer management systems for the recreational industry. This new agreement exemplifies how the breadth of offerings from Global Payments enables growth for its partners as they look to expand their payments program and deliver innovative experiences to their customers. Since 2009, Lightspeed has partnered with Worldpay, now Global Payments, to provide payment and security services to its customer base. This relationship has been built on a consultative and collaborative approach, with Glob

Quincy, MA, May 08, 2026 (GLOBE NEWSWIRE) -- Stran & Company, Inc. ("Stran" or the "Company") (NASDAQ:SWAG) (NASDAQ:SWAGW), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today announced that it will host a conference call at 10:00 A.M. Eastern Time on Wednesday, May 13, 2026, to discuss the Company's financial results for the first quarter of 2026 ended March 31, 2026, as well as the Company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and using entry code: 643227. A

Company Plans to Leverage Proprietary Dataset to Build Scalable AI-Powered Revenue Model BOSTON, MA, May 08, 2026 (GLOBE NEWSWIRE) -- Netcapital Inc. (NASDAQ:NCPL) ("Netcapital" or the "Company"), a publicly traded fintech company, today announced a fundamental transformation of its business model designed to unlock scalability and drive increased revenue growth. Under the leadership of recently appointed CEO Todd Violette, Netcapital plans to evolve from a transaction-based capital formation marketplace into a comprehensive, data-driven capital markets infrastructure platform. We expect this transformation to leverage the Company's most valuable asset: a proprietary dataset built from p

Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated first half 2026CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with gemcitabine in high-risk (HR) NMIBC BCG-exposed and BCG-unresponsive to be presented at AUA 2026Well-positioned to deliver on key milestones with approximately $1.1 billion cash, cash equivalents and marketable securities sufficient to fund operations through 2029 DALLAS, May 08, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today reported fin